RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Published on Dec 1, 2019in Journal of Experimental & Clinical Cancer Research5.646
路 DOI :10.1186/s13046-018-1001-2
Marco Infante2
Estimated H-index: 2
Alessandra Fabi30
Estimated H-index: 30
+ 3 AuthorsAndreaFabbri41
Estimated H-index: 41
RANKL/RANK/OPG system consists of three essential signaling molecules: i) the receptor activator of nuclear factor (NF)-kB-ligand (RANKL), ii) the receptor activator of NF-kB (RANK), and iii) the soluble decoy receptor osteoprotegerin (OPG). Although this system is critical for the regulation of osteoclast differentiation/activation and calcium release from the skeleton, different studies have elucidated its specific role in mammary gland physiology and hormone-driven epithelial proliferation during pregnancy. Of note, several data suggest that progesterone induces mammary RANKL expression in mice and humans. In turn, RANKL controls cell proliferation in breast epithelium under physiological conditions typically associated with higher serum progesterone levels, such as luteal phase of the menstrual cycle and pregnancy. Hence, RANKL/RANK system can be regarded as a major downstream mediator of progesterone-driven mammary epithelial cells proliferation, potentially contributing to breast cancer initiation and progression. Expression of RANKL, RANK, and OPG has been detected in breast cancer cell lines and in human primary breast cancers. To date, dysregulation of RANKL/RANK/OPG system at the skeletal level has been widely documented in the context of metastatic bone disease. In fact, RANKL inhibition through the RANKL-blocking human monoclonal antibody denosumab represents a well-established therapeutic option to prevent skeletal-related events in metastatic bone disease and adjuvant therapy-induced bone loss in breast cancer. On the other hand, the exact role of OPG in breast tumorigenesis is still unclear. This review focuses on molecular mechanisms linking RANKL/RANK/OPG system to mammary tumorigenesis, highlighting pre-clinical and clinical evidence for the potential efficacy of RANKL inhibition as a prevention strategy and adjuvant therapy in breast cancer settings.
  • References (168)
  • Citations (1)
馃摉 Papers frequently viewed together
12 Citations
32 Citations
16 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Tilman D. Rachner (DKFZ: German Cancer Research Center)H-Index: 18
#2Sabine Kasimir-Bauer (University of Duisburg-Essen)H-Index: 25
Last. Ann-Kathrin Bittner (University of Duisburg-Essen)H-Index: 4
view all 11 authors...
Background: We assessed serum concentrations of the receptor activator of nuclear factor kappa-B ligand (RANKL) and its decoy receptor osteoprotegerin (OPG), two proteins implicated in the development and progression of breast cancer (BC), in 509 patients with primary, non-metastatic BC. Then the results were evaluated with regards to the occurrence of bone metastases, the presence of disseminated tumor cells (DTC) in the bone marrow, survival and risk of developing metastatic disease. Patients ...
3 CitationsSource
#1Anastasios D. Papanastasiou (University of Patras)H-Index: 12
#2Chaido Sirinian (University of Patras)H-Index: 7
Last. Haralabos P. Kalofonos (University of Patras)H-Index: 40
view all 3 authors...
After the publication of this article [1] we noticed that in Fig.聽1, the gel images (1A and 1B lower panel) were incorrect.
1 CitationsSource
#1Danja Sarink (DKFZ: German Cancer Research Center)H-Index: 2
#2Helena Schock (DKFZ: German Cancer Research Center)H-Index: 15
Last. Ren茅e T. Fortner (DKFZ: German Cancer Research Center)H-Index: 16
view all 35 authors...
This project was funded by research grant #111454 from the Deutsche Kresbshilfe. RT Fortner was supported by a Marie Curie International Incoming Fellowship of the European Commission鈥檚 Seventh Framework Programme (MC-IIF-623984). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle...
2 CitationsSource
#1Chaido Sirinian (University of Patras)H-Index: 7
#2Anastasios D. Papanastasiou (University of Patras)H-Index: 12
Last. Haralabos P. Kalofonos (University of Patras)H-Index: 40
view all 9 authors...
The RANK/RANKL axis emerges as a key regulator of breast cancer initiation, progression, and metastasis. RANK-c is a RANK receptor isoform produced through alternative splicing of the TNFRSF11A (RANK) gene and a dominant-negative regulator of RANK-induced nuclear factor-魏B (NF-魏B) activation. Here we report that RANK-c transcript is expressed in 3.2% of cases in The Cancer Genome Atlas breast cancer cohort evenly between ER-positive and ER-negative cases. Nevertheless, the ratio of RANK to RANK-...
3 CitationsSource
#1Robert L. Coleman (University of Sheffield)H-Index: 92
#2Dianne M. Finkelstein (Harvard University)H-Index: 72
Last. Arlene Chan (The Breast Cancer Research Foundation)H-Index: 28
view all 9 authors...
501Background: Denosumab (Dmab) is a potent RANK ligand inhibitor approved for the management of treatment induced bone loss in early breast (EBC) and prevention of skeletal morbidity associated with metastatic bone disease. Preclinical data suggested that Dmab could prevent development of bone metastases. This trial evaluated the addition of Dmab to standard (neo)adjuvant therapy for high-risk EBC patients (pts). Methods: 4509 pts with EBC (93.5% node+) from 407 centers were randomized to stand...
30 CitationsSource
#1Michael Gnant (Medical University of Vienna)H-Index: 73
#2Georg Pfeiler (Medical University of Vienna)H-Index: 23
Last. Christian F. Singer (Medical University of Vienna)H-Index: 53
view all 20 authors...
500Background: Adjuvant aromatase inhibitors (AI) are standard of care for postmenopausal women with hormone receptor positive (HR+) early stage breast cancer but cause osteoporosis and fractures. ABCSG-18 showed previously that adjuvant denosumab significantly reduces clinical fractures (primary endpoint, HR = 0.5, p < 0.0001, Lancet 2015). Here, we present the impact of adjuvant denosumab on disease-free survival. Patients and Methods: 3,425 postmenopausal patients with early HR+ BC receiving ...
16 CitationsSource
#1Emma D. Deeks (Springer Science+Business Media)H-Index: 18
Compliance with Ethical Standards Disclosure The preparation of this review was not supported by any external funding. Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Additional information about this Adis Drug Review can be found here. Abstract Denosumab (Prolia庐; Pralia庐) is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection o...
4 CitationsSource
#1A. F. de Groot (LUMC: Leiden University Medical Center)H-Index: 3
#2N.M. Appelman-Dijkstra (LUMC: Leiden University Medical Center)H-Index: 1
Last. Judith R. Kroep (LUMC: Leiden University Medical Center)H-Index: 28
view all 4 authors...
Abstract At present, accumulating evidence suggests that inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) does not only induce an increase in bone mass and strength, but also has anti-tumor effects. Denosumab, an antibody targeting RANKL, is used to treat osteoporosis and to prevent skeletal related events (SREs) in patients with bone metastases originating from solid tumors. However, expression of RANKL and its receptor activator of nuclear factor kappa-B (RANK) is not ...
25 CitationsSource
#1Shuan RaoH-Index: 9
#2Shane J. F. CroninH-Index: 12
Last. Josef M. PenningerH-Index: 127
view all 4 authors...
The tumor necrosis factor (TNF) receptor RANK (TNFRSF11A) and its ligand RANKL (TNFSF11) regulate osteoclast development and bone metabolism. They also control stem cell expansion and proliferation of mammary epithelial cells via the sex hormone progesterone. As such, RANKL and RANK have been implicated in the onset of hormone-induced breast cancer. Recently, RANK/RANKL were identified as crucial regulators for BRCA1 mutation-driven breast cancer. Current prevention strategies for BRCA1 mutation...
13 CitationsSource
#1Andrew Gdowski (University of North Texas Health Science Center)H-Index: 6
#2Amalendu Prakash Ranjan (University of North Texas Health Science Center)H-Index: 14
Last. Jamboor K. Vishwanatha (University of North Texas Health Science Center)H-Index: 34
view all 3 authors...
Elucidation of mechanisms regulating bone metastasis has progressed significantly in recent years and this has translated to many new therapeutic options for patients with bone metastatic cancers. However, the rapid rate of progress in both the basic science literature and therapies undergoing clinical trials makes staying abreast with current developments challenging. This review seeks to provide an update on the current state of the science in bone metastasis research and give a snap shot of t...
20 CitationsSource
Cited By1
#1Emanuela Galliera (University of Milan)H-Index: 18
#2Luca Massaccesi (University of Milan)H-Index: 9
Last. Giuseppe BanfiH-Index: 34
view all 7 authors...
#1Paloma Y谩帽ez-Sede帽o (Complutense University of Madrid)H-Index: 28
#2Alejandro Valverde (Complutense University of Madrid)H-Index: 4
Last. Jos茅 M. Pingarr贸n (Complutense University of Madrid)H-Index: 48
view all 8 authors...
#1Minyue Bao (Sichuan University)H-Index: 2
#2Kaiwen Zhang (Sichuan University)
Last. Ling Ye (Sichuan University)H-Index: 6
view all 7 authors...
#1Negin Amin (KAUMS: Kashan University of Medical Sciences)H-Index: 1
#2Cain C.T. Clark (Coventry University)H-Index: 5
Last. Sadegh Djafarnejad (KAUMS: Kashan University of Medical Sciences)
view all 4 authors...
Abstract Background To this day, empirical data suggests that zinc has important roles in matrix synthesis, bone turnover, and mineralization and its beneficial effects on bone could be mediated through different mechanisms. The influence of zinc on bone turnover could be facilitated via regulating RANKL/RANK/OPG pathway in bone tissue. Therefore, the aim of the study was to conduct a review to investigate the possible effect of the zinc mediated bone remodeling via RANKL/RANK/OPG pathway. Metho...